Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: Asthma and Chronic Obstructive Pulmonary Disease (COPD) are major global health issues, impacting morbidity, mortality, and healthcare costs. Despite the proven benefits of pharmacist involvement in managing these conditions, their potential in hospitals remains underused. This study aimed to identify patients at high risk of rehospitalization post-exacerbation of asthma or COPD, to target pharmaceutical interventions.
Methods: Data from the University Hospital for January-December 2019 on adult admissions for asthma/COPD were analyzed, focusing on demographics, hospitalization, and clinical outcomes.
Results: Among the 140 patients enrolled, a significant majority (91%) underwent adjustments in their treatment regimens during their hospital stay, and nearly 59% faced readmission within six months. A survival analysis highlighted a notable disparity in the rates of rehospitalization-free survival between patients with asthma and those with COPD, identifying COPD patients as having a higher susceptibility to rehospitalization.
Conclusion: The study found COPD patients at greater risk but did not specify a priority profile, suggesting the necessity for broad, customized interventions to improve outcomes and reduce healthcare strain.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pharma.2025.02.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Formoterol, a clinically approved drug, inhibits ferroptosis by suppressing lipid peroxidation and attenuates APAP-induced acute liver injury.
Chem Biol Interact
September 2025
College of Chemistry, Chemical Engineering and Materials Science, Key Laboratory of Molecular and Nano Probes, Ministry of Education, Shandong Provincial Key Laboratory of Clean Production of Fine Chemicals, Shandong Normal University, Jinan, 250014, China. Electronic address:
Ferroptosis is an iron-dependent form of regulated cell death characterized by lethal lipid peroxidation and implicated in various human diseases. Despite intensive research, clinically applicable ferroptosis inhibitors remain unavailable. In this study, we identify formoterol, a β-adrenergic agonist widely used to treat asthma and COPD, as a potent and selective ferroptosis inhibitor through scaffold-based screening of FDA-approved drugs.
View Article and Find Full Text PDFAir pollution and diseases: signaling, G protein-coupled and Toll like receptors.
Pharmacol Ther
September 2025
Department of Molecular Pharmacology, University of Groningen, Groningen, the Netherlands; Groningen Research Institute for Asthma and COPD, GRIAC, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Electronic address:
Air pollution is a significant public health issue that impacts lung health, particularly in vulnerable populations such as children, the elderly, and individuals with pre-existing respiratory conditions. Both natural and anthropogenic sources of air pollution give rise to a variety of toxic compounds, including particulate matter (PM), ozone (O₃), sulfur dioxide (SO₂), nitrogen dioxide (NO₂), carbon monoxide (CO), and polycyclic aromatic hydrocarbons (PAHs). Exposure to these pollutants is strongly associated with the development and exacerbation of respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), lung cancer, and idiopathic pulmonary fibrosis (IPF).
View Article and Find Full Text PDFAssociations between PM from prescribed burning and emergency department visits in 11 Southeastern US states.
Environ Int
September 2025
Department of Environmental Health, Boston University School of Public Health, 715 Albany Street, Boston, MA 02118, USA. Electronic address:
Longer, more severe wildfire seasons are becoming the norm in fire-prone areas. Prescribed burning is a tool used to mitigate wildfire spread. However, prescribed burning also contributes to air pollution, including PM (particulate matter with aerodynamic diameter <= 2.
View Article and Find Full Text PDFAssessing inpatient formulary-driven inhaler use in presumed Group B chronic obstructive pulmonary disease.
J Am Pharm Assoc (2003)
September 2025
WVU Medicine - WVU Hospitals; Morgantown, WV; West Virginia University School of Pharmacy; Morgantown, WV.
Background: Long-acting muscarinic antagonist (LAMA) and long-acting beta agonist (LABA) combination maintenance therapy is recommended for patients with Group B chronic obstructive pulmonary disease (COPD) in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. Exposure to inhaled corticosteroids (ICS) in these patients may increase adverse effects without adding clinical benefit. Inpatient formulary limitations may facilitate unnecessary exposure to ICS and ICS-associated adverse events while hindering the use of optimal LAMA/LABA inhaler therapy in Group B COPD patients.
View Article and Find Full Text PDFInhaled Cannabis, Asthma, and Chronic Obstructive Pulmonary Disease: A Population-Based Cross-Sectional Study of n = 379,049.
J Gen Intern Med
September 2025
Center for Data to Discovery and Delivery Innovation (3DI), San Francisco VA Health Care System, San Francisco, CA, USA.
Background: Cannabis may cause chronic pulmonary disease. Prior studies have been limited by low cannabis exposure, lack of data on tobacco cigarettes, and/or limited numbers of those without tobacco cigarette use.
Objective: To examine whether inhaled cannabis associated with asthma and chronic obstructive pulmonary disease, independent of tobacco cigarettes.